For example, using web analytics services that leverage these Tools helps us to understand how user engagement with and navigate of our Site, e.g., the number of visitors to a page and when. This data may be used as well as to guide our advertising decisions. This information is used for user experience purposes, where it serves to provide Heska a better understanding of customer behavior and where this customer behavior information will drive customization and improvement of the user experience with our websites, services and offerings. To learn more, visit and connect with us on Facebook, Instagram, LinkedIn, and Twitter.Cookies and Tools: Heska and its business partners collect information about you by using cookies, tracking pixels and other technologies (collectively, “Tools”). The test is currently recommended as an annual screening test for dogs at higher risk of cancer due to age and/or breed, and as an aid-in-diagnosis for dogs in which cancer is suspected based on clinical signs or other clinical findings. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients. The company's flagship product, OncoK9® – The Liquid Biopsy Test for Dogs™, enables veterinarians to detect cancer in dogs with a simple blood draw. PetDx® – The Liquid Biopsy Company for Pets™ is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The test is available at veterinary clinics across the United States and Canada.About PetDx Today, blood samples from all over the country are shipped daily to the PetDx central laboratory in San Diego, and results are delivered to ordering veterinarians within 10 business days. Since its launch in 2021, OncoK9 has been successfully integrated into routine testing at thousands of leading veterinary practices nationwide as a new preventive care and aid-in-diagnosis tool. It can detect 30 different types of canine cancer, with sensitivity of 85.4% for three of the most aggressive cancers (lymphoma, hemangiosarcoma, and osteosarcoma) and overall sensitivity of 54.7%, at a specificity of 98.5% (corresponding to a false positive rate of just 1.5%). The study demonstrated that the performance of OncoK9 mirrors that of leading MCED tests for humans. The CANcer Detection in Dogs (CANDiD) study-the largest clinical validation study in veterinary cancer diagnostics-was performed on blood samples collected prospectively from more than 1,000 client-owned dogs at more than 40 clinical sites on four continents.
#Antech diagnostics logo full
PetDx recently published the full results of a landmark study designed to validate the test's performance in PLOS ONE, a peer-reviewed open-access scientific journal from the Public Library of Science. "OncoK9 will be a valuable tool for our customers to use as they both screen for and work to diagnose suspected cancers, likely helping extend the lives of many dogs." "Cancer takes too many dogs far too soon, and early diagnosis and treatment are the best defense against that," said Cathy Meeks, DVM, DACVIM, Vice President, Medical Operations, Antech Diagnostics. It employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) of blood-derived DNA. OncoK9 is a first-in-class multi-cancer early detection test that enables veterinarians to detect cancer in dogs with a simple blood draw. "Our relationship with Antech broadens access to this breakthrough innovation and is expected to have a profound impact on dogs, the people who love them, and the veterinarians looking to provide the very best care for their patients." "Cancer is by far the leading cause of death in dogs and the vast majority of cases are diagnosed after the onset of clinical signs, by which time the cancer is often advanced and the chances of achieving a cure or long-term control are low," said PetDx Founder and CEO Daniel S. SAN DIEGO, J/PRNewswire/ - PetDx® – The Liquid Biopsy Company for Pets™ and Antech® Diagnostics jointly announce that they have entered into an agreement to make OncoK9®, the pioneering multi-cancer early detection (MCED) test for dogs, available to all Antech customers across North America.
The strategic relationship announced today makes OncoK9 immediately available to all Antech customers in the United States and Canada
0 kommentar(er)
